Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESOLVE: CK0802 in COVID-19 Induced ARDS
NCT04468971Phase 1Completed
- Start
- Sep 2020
- Primary completion
- Oct 2021
- Modality
- Regulatory T Cells (Tregs)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CK0802 in coronavirus disease 2019 (COVID-19) and acute respiratory distress syndrome (ARDS) (3 arms). Primary endpoints: Regimen related >= grade 3 toxicity within 48 hours of first infusion and 28-day treatment success (S28). Started Sep 2020; status: completed.
02
Drugs
CK0802
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT04468971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04468971.